Champions Oncology is a biotechnology business based in the US. Champions Oncology shares (CSBR) are listed on the NASDAQ and all prices are listed in US Dollars. Champions Oncology employs 230 staff and has a trailing 12-month revenue of around $49.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.81 |
|---|---|
| 52-week range | $4.50 - $7.13 |
| 50-day moving average | $4.85 |
| 200-day moving average | $5.35 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.81 from 2024-07-25
| 1 week (2024-07-19) | -4.66% |
|---|---|
| 1 month (2024-06-27) | -4.75% |
| 3 months (2024-04-26) | -4.18% |
| 6 months (2024-01-26) | -23.10% |
| 1 year (2023-07-27) | -25.66% |
|---|---|
| 2 years (2022-07-27) | -43.41% |
| 3 years (2021-07-27) | 10.41 |
| 5 years (2019-07-26) | 6.91 |
| Revenue TTM | $49.2 million |
|---|---|
| Gross profit TTM | $24.3 million |
| Return on assets TTM | -17.48% |
| Return on equity TTM | -388.65% |
| Profit margin | -19.76% |
| Book value | $-0.15 |
| Market Capitalization | $68.6 million |
TTM: trailing 12 months
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $4.5 up to $7.1303. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 0.493. This would suggest that Champions Oncology's shares are less volatile than average (for this exchange).
Champions Oncology, Inc. , a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool. The company markets its products through internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.